Xeris Biopharma (XERS) to Release Earnings on Monday

Xeris Biopharma (NASDAQ:XERS) is projected to announce its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.03 per share and revenue of $86.00 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Xeris Biopharma Trading Down 1.8%

Shares of Xeris Biopharma stock opened at $6.61 on Monday. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -66.09 and a beta of 0.52. The firm’s 50-day moving average price is $7.28 and its two-hundred day moving average price is $7.66. Xeris Biopharma has a 1-year low of $3.58 and a 1-year high of $10.08.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on XERS. Oppenheimer restated an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Zacks Research cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Barclays initiated coverage on shares of Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research report on Friday, January 9th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Xeris Biopharma has a consensus rating of “Moderate Buy” and an average target price of $10.08.

Insider Activity at Xeris Biopharma

In related news, Director John Johnson sold 135,400 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $7.22, for a total value of $977,588.00. Following the transaction, the director directly owned 698,083 shares in the company, valued at $5,040,159.26. This represents a 16.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.08, for a total transaction of $176,341.56. Following the completion of the transaction, the insider directly owned 2,705,346 shares in the company, valued at approximately $19,153,849.68. The trade was a 0.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 240,308 shares of company stock worth $1,745,120. Insiders own 4.56% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Corient Private Wealth LLC bought a new stake in Xeris Biopharma in the fourth quarter valued at about $84,000. VARCOV Co. acquired a new position in shares of Xeris Biopharma during the 4th quarter worth about $243,000. Virtus Investment Advisers LLC increased its stake in shares of Xeris Biopharma by 44.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 37,102 shares of the company’s stock valued at $291,000 after acquiring an additional 11,358 shares during the last quarter. Millennium Management LLC increased its stake in shares of Xeris Biopharma by 63.7% in the 4th quarter. Millennium Management LLC now owns 859,051 shares of the company’s stock valued at $6,744,000 after acquiring an additional 334,302 shares during the last quarter. Finally, Man Group plc acquired a new stake in shares of Xeris Biopharma in the 4th quarter valued at approximately $375,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.